Share-based Payment Arrangement, Expense of Bolt Biotherapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bolt Biotherapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • Bolt Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $407,000, a 63% decline year-over-year.
  • Bolt Biotherapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,923,000, a 65% decline year-over-year.
  • Bolt Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $7,407,000, a 20% decline from 2023.
  • Bolt Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $9,223,000, a 3.7% decline from 2022.
  • Bolt Biotherapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,576,000, a 13% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Bolt Biotherapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,923,000 $407,000 -$691,000 -63% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $3,614,000 $625,000 -$2,200,000 -78% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $5,814,000 $709,000 -$1,593,000 -69% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $7,407,000 $1,182,000 -$886,000 -43% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $8,293,000 $1,098,000 -$1,231,000 -53% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $9,524,000 $2,825,000 +$475,000 +20% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $9,049,000 $2,302,000 -$174,000 -7% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $9,223,000 $2,068,000 -$55,000 -2.6% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $9,278,000 $2,329,000 +$186,000 +8.7% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $9,092,000 $2,350,000 -$41,000 -1.7% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $9,133,000 $2,476,000 -$443,000 -15% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $9,576,000 $2,123,000 -$19,000 -0.89% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $9,595,000 $2,143,000 -$83,000 -3.7% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $9,678,000 $2,391,000 +$368,000 +18% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $9,310,000 $2,919,000 +$810,000 +38% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $8,500,000 $2,142,000 +$1,573,000 +276% 01 Oct 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $6,927,000 $2,226,000 +$1,823,000 +452% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $5,104,000 $2,023,000 +$1,800,000 +807% 01 Apr 2021 30 Jun 2021 10-Q 10 Aug 2022 2022 Q2
Q1 2021 $3,304,000 $2,109,000 +$1,884,000 +837% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $1,420,000 $569,000 01 Oct 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
Q3 2020 $403,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $223,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $225,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

Bolt Biotherapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $7,407,000 -$1,816,000 -20% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $9,223,000 -$353,000 -3.7% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $9,576,000 +$1,076,000 +13% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $8,500,000 +$7,080,000 +499% 01 Jan 2021 31 Dec 2021 10-K 29 Mar 2023 2022 FY
2020 $1,420,000 01 Jan 2020 31 Dec 2020 10-K 30 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.